Compare Theralase Technologies, Inc. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
CAD 60 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.34
-188.80%
30.98
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Mar 2026)
Net Profit:
-1 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-25.4%
0%
-25.4%
6 Months
51.61%
0%
51.61%
1 Year
23.68%
0%
23.68%
2 Years
23.68%
0%
23.68%
3 Years
-16.07%
0%
-16.07%
4 Years
-21.67%
0%
-21.67%
5 Years
-2.08%
0%
-2.08%
Theralase Technologies, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-1.65%
EBIT Growth (5y)
4.76%
EBIT to Interest (avg)
-4.83
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.03
Sales to Capital Employed (avg)
0.56
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.05%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
30.98
EV to EBIT
-16.07
EV to EBITDA
-17.27
EV to Capital Employed
46.53
EV to Sales
59.74
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-289.57%
ROE (Latest)
-188.80%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Dec 2022
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.05%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
0.10
0.10
Operating Profit (PBDIT) excl Other Income
-1.00
-1.40
28.57%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.00
-1.50
33.33%
Operating Profit Margin (Excl OI)
-7,768.90%
-16,313.10%
854.42%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 0.00% vs -50.00% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 33.33% vs -15.38% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
0.80
1.00
-20.00%
Operating Profit (PBDIT) excl Other Income
-3.90
-4.00
2.50%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-4.10
-4.30
4.65%
Operating Profit Margin (Excl OI)
-5,113.90%
-4,149.60%
-96.43%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -20.00% vs -9.09% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 4.65% vs 6.52% in Dec 2024
About Theralase Technologies, Inc. 
Theralase Technologies, Inc.
Pharmaceuticals & Biotechnology
Theralase Technologies Inc. is a biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (PDCs) to destroy cancer. The Company operates through two divisions: Therapeutic Laser Technology (TLT) division and Photo Dynamic Therapy (PDT) division. The TLT division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology is used for healing a range of nerve, muscle and joint conditions, including arthritis, osteoarthritis and wounds. The PDT division develops PDCs and activates them with laser technology to destroy specifically targeted cancers and bacteria. Its TLC-2000 Biofeedback Therapeutic Laser Technology possesses Cell Sensing technology that senses and targets injured tissue. It is also developing TLC-1000 therapeutic medical laser system. It is developing TLC-3000 medical laser system for the treatment of a range of cancers.
Company Coordinates 
Company Details
41 Hollinger Rd , EAST YORK ON : M4B 3G4
Registrar Details






